OncoMatch/Clinical Trials/NCT07138755
The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
Is NCT07138755 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Experimental for nsclc.
Treatment: Experimental — To evaluate the Efficacy and Safety of the Combination of Sintilimab With Platinum-doublet Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: EGFR wild-type
Required: HER2 (ERBB2) wild-type
Required: MET wild-type
Required: ROS1 wild-type
Disease stage
Required: Stage III
Demographics
Prior therapy
Cannot have received: systematic anti-tumor treatment
No previous systematic anti-tumor treatment or chest radiotherapy for NSCLC
Cannot have received: chest radiotherapy
No previous systematic anti-tumor treatment or chest radiotherapy for NSCLC
Cannot have received: thoracic radiotherapy
Previously received local treatments for tumor lesions such as thoracic radiotherapy and radiofrequency ablation
Cannot have received: radiofrequency ablation
Previously received local treatments for tumor lesions such as thoracic radiotherapy and radiofrequency ablation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07138755 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ALK?
Yes, ALK wild-type is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR wild-type is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage III is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages